The Trucheck™ Intelli can detect over 70 types of cancer. Including the most common cancers; breast, bowel, prostate, ovarian, and lung cancers (see full list below).

Trucheck™ cannot detect blood or lymphatic system cancers because CTCs are associated with solid organ malignancies.

Trucheck™ Intelli has been validated for the detection of the following types of cancer:

• Adenocarcinoma ( Salivary Duct, Thyroid, Breast, lung, Oesophagus, Stomach, Duodenum,
  Jejunum, Ileum, Colon, Rectum, Pancreas, Gallbladder, Bile Duct, Liver, Ovary, Prostate, Uterus);
• Squamous Cell Carcinoma (SCC; Buccal Mucosa, Hard Palate, Larynx, Lip, Oral Cavity, Paranasal Sinus, Pharynx, Pyriform Fossa, Retromolar Trigone, Soft palate, Tongue, Tonsil, Oesophagus, Lung, Penis, Cervix, Vulva, Vagina, Anorectal, Skin);
• Adenosquamous Carcinoma (Oesophagus, Lung);
• Neuroendocrine (Lung, Esophagus, Duodenum, Jejunum, lleum, Thymus, Adrenal, Pancreas, Prostate, Colon, Rectum);
• Renal Cell Carcinoma (Kidney);
• Transitional Cell Carcinoma (Bladder, Renal Pelvis, Ureter);
• Gastrointestinal Stromal tumors (Stomach, Duodenum, lleum, Jejunum, Colon, Rectum);
• Melanomas (Cutaneous, Mucosal);
• Mesothelioma (Plural, Peritoneal);
• Sarcomas (Carcinosarcoma, Chondrosarcoma, Leiomyosarcoma, Osteosarcoma, Liposarcoma);
• Small Cell Lung Cancer (Lung);
• Glioma.

Trucheck™ Femmesafe test screens for a limited number of cancers in women.

• Adenocarcinoma of Breast
• Adenocarcinoma of the Ovary
• Adenocarcinoma of the Uterus
• Squamous cell carcinoma of Cervix.

Age is a significant risk factor for nearly all cancers. We want to target these cancer screening tests at people likely to benefit from testing.

Trucheck™ Intelli: Adults over 40 years of age

Trucheck Femmesafe: Females over 40 years of age

Individuals aged 35 to 39 years of age, only if ONE of the risk factors below apply

• • A family history of cancer and/or known carrier status
  • Presence of risk associated Hereditary germline mutation/s
  • Obesity (BMI over 30)
  • Type 2 diabetes
  • History of Infectious Diseases (HPV, hepatitis B or hepatitis C viruses)
  • Documented/ significant exposure to specific chemicals and carcinogens

The laboratory will usually share your results with your doctor within 2 weeks. At your test consultation, you can decide with your doctor how you would like to receive your results. We offer all patients a free face to face follow-up consultation. If you prefer you may decide with your doctor to receive your results by telephone. 

A positive result means CTCs indicative of Trucheck™ positivity have been detected in your sample, which is suggestive of a higher chance of detection of malignancy (cancer). The sample result will also usually suggest the likely organ of origin and cancer type.

Your doctor will discuss with you suitable next steps to confirm if cancer is present. This will usually mean considering further diagnostic tests such as scans and biopsies.

A negative result means CTCs were not detected in your sample. The chance of having an active malignancy present in the body is low.
A negative Trucheck report does not completely rule out the possibility of cancer as some cancers may not she detectable tumour cells in the blood.

You can enjoy the peace of mind given by the negative test result.

No. The test is designed for people without symptoms. If you have symptoms, you should seek urgent medical advice.

In the future, the tests may be used to help guide which patients with symptoms need further checks such as a biopsy but this is still at a research stage.

In studies, the test is positive in both early and late-stage cancers. This is good because many current tests only detect cancers when they are at an advanced or late stage. Early diagnosis is likely to make treatment more successful.

No. It is only suitable for people who have not had cancer.

There are other similar tests available to monitor patients after cancer treatment. We would recommend you speak with your treating doctor or surgeon to see if there is a test suitable for you.

It can be a useful addition to your yearly health screening or medical check-up. You should discuss this with your Doctor how often or when is the right time for you to test.

No. Trucheck™ tests are designed to be used in addition to, and not replace, conventional cancer screening. This includes standard tests such as mammograms, cervical screening and bowel cancer screening. 

Trucheck™ can detect cancers at an early stage before symptoms appear.

• Trucheck™ Intelli is a blood test that can detect more than 70 types of early-stage cancer within the asymptomatic population.
  • Trucheck Intelli has an overall sensitivity of 88.2% – meaning that for every 100 patients tested who have cancer, it will correctly identify 88 of those patients, resulting in a 12% false negative rate.
• Trucheck™ Femmesafe is a blood test that can detect adenocarcinoma (cancer) of the breast, uterus, ovary and squamous cell carcinoma of the cervix in asymptomatic women.
  • Trucheck Breast has a sensitivity of 88.2% – meaning that for every 100 patients tested who have cancer, it will correctly identify 88 of those patients, resulting in a 12% false negative rate.

All Trucheck tests have a specificity of 96% – meaning that for every 100 people tested, that do not have cancer, Trucheck will correctly identify 96 of these individuals, resulting in a 4% false positive rate.

False positives occur in all screening tests, the 4% level in Trucheck tests compares very favourably with other cancer screening such as PSA testing (75%), FIT testing (25%) and mammograms (7-12% at first mammogram).

Yes, we believe the Cancer Screening blood test is a really powerful addition to our health screening. It is not designed to replace standard health screening tests so should be done alongside your routine healthcare. Check out our packages here.

If you have more questions about the test itself then the laboratory has lots of detailed scientific information available here.

The total fees include your pre and post-test consultations with the doctor at our clinic, sample taking and all laboratory and report fees.

Trucheck™ Intelli – up to 70 solid tumours – £1250

Trucheck™ Femmesafe – £950

In the event of positive results showing a high risk of cancer it is likely that further checks such as scans or biopsies are likely to be recommended. These tests may not be covered by private medical insurance or provided by the NHS, especially prior to a cancer diagnosis.

Our genetic screening tests over 70 gene variants that can predispose to cancer and tell us about how your body reacts to drugs. Importantly, all of these gene variants can be acted upon to help prevent or reduce the risk of the condition. Or for the pharmacogenetic genes can help guide drug treatment either now or in the future. 

Providing a DNA sample is very simple. 

The sample depends on the test chosen.

51 cancer gene screening PLUS pharmacogenomics uses a normal blood sample.

31 cancer gene screening uses a saliva test. Taken in clinic you simply spit into the tube.

We work with two specialist genetic testing laboratories who both registered and highly respected for specialist genetic testing. The laboratories uses the highest standard of genetic testing called NGS (next generation sequencing). This is the most accurate method. Some online DNA testing and family history companies use other methods such ‘genotyping’; this leads to more common false positive and negative results. They can be fun and quick to use but are not meant to guide medical decisions or healthcare.

We expect your laboratory report to be available within 6 weeks of your appointment. We will contact you when it is available to arrange a follow-up consultation. 

The Association of British insurers and the British Medical Association have agreed on a set of questions that insurers can ask your GP when you apply for life insurance. Your GP will be asked about any medical condition that you have suffered in the past or are currently experiencing that may reduce your life expectancy. They are also allowed to ask you and your GP about your family history. They are not allowed to ask or request the results of any predictive genetic testing. 

Currently, the only exception in the UK to this is if you are applying for insurance with the only exception being if you are applying for life insurance over £500,000 and you have had a predictive genetic test for Huntington’s Disease. Only in this circumstance do you need to tell the insurance company the result of the test, if they ask.

If you have a strong family history of breast cancer for example and you test negative for genes related to this it may be in your interest to disclose this and you may choose to do this. You can read more about the code of the Association of British Insurers here.

There are two possible outcomes from our cancer gene testing:

Negative and positive.

If the result is negative it means that the test did not pick up any genes that increase the risk of disease. It doesn’t mean that you will never develop one of the conditions tested for, as there are many other factors aside from genes that can contribute to developing a disease. As we learn more about genetics and disease, it may be that your test results in the future will be updated to reflect new medical information. If this is the case, we will inform you immediately. 

A positive result means you have discovered a gene variant that increases the risk of you developing a certain cancer. You will then be able to work with your doctor to determine what the next steps are for you. This may include options to prevent disease or increased surveillance to detect the disease at an earlier, more treatable stage. 

Your pharmacogenetic testing will likely show several different variants, in your report there will be detailed recommendations on medications. This might include advice to reduce doses or consider alternative medicines for common drugs such as cholesterol medicines, pain killers and antidepressants.

We ensure the highest level of security for your personal information. Full details of our privacy policy are available here. We use our patient portal to securely share copies of your results by email. We can use an alternative method of communication if you wish – just let us know.

The genetic testing laboratory receive your personal information and abide by the extremely strict rules on privacy of sensitive data. You must consent to their receiving and sharing your personal information and data. You may choose to opt-out of anonymised research studies.

We only use medical-grade genetic testing. We use a leading specialist laboratories, who are fully accredited to ISO 15189 and 17025.

Our genetic testing uses both full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS). This is the most accurate method. Some online DNA testing and family history companies use other methods such ‘genotyping’; this leads to more common false positive and negative results. They can be fun and quick to use but are not meant to guide medical decisions or healthcare.

51 cancer gene screening PLUS pharmacogenomics  – £1300

31 cancer gene screening – £900

Fees include pre test consultation with the doctor, review of medical and family history, and sample taking. Laboratory analysis. Full report and advice on further screening or risk reduction for any positive cancer risk genes.  Detailed report on your pharmacogenetics including advice on medications, dosages, side effects and alternatives.

Follow-up consultation with the doctor at our clinic to discuss your results. Including advice on further referrals and any other health screening indications.

Yes we believe genetic screening is a really powerful addition to our health screening. Check out our packages here.

Tumour genes include those related to:

Breast cancer

Ovarian cancer

Uterine cancer

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Pancreatic cancer

Prostate cancer

Renal cell cancer

Thyroid cancer

Full List of Genes Tested

Tumour genes include those related to:

Breast cancer

Ovarian cancer

Uterine cancer

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Pancreatic cancer

Prostate cancer

Renal cell cancer

Thyroid cancer

Full List of Genes Tested

Tumour genes include those related to:

Breast cancer

Ovarian cancer

Uterine cancer

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Pancreatic cancer

Prostate cancer

Renal cell cancer

Thyroid cancer

Full List of Genes Tested

APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL

Tumour genes include those related to:

Breast cancer

Ovarian cancer

Uterine cancer

Colorectal cancer

Cutaneous melanoma

Gastric cancer

Pancreatic cancer

Prostate cancer

Renal cell cancer

Thyroid cancer

Full List of Genes Tested

Pharmacogenetics illustrates how genetic changes can affect the influence of drugs. Genetic changes in the proteins responsible for absorption, distribution, metabolism, and excretion of drugs can have a huge impact on their effectiveness and compatibility. Some drugs have different effects on different people, e.g. antidepressants, analgesics, neuroleptics, chemotherapeutics, AIDS medication, thrombosis medication, anaesthetics, beta-blockers, and statins. Reduced or missing activity of a specific enzyme may increase the drug dosage and cause unwanted side effects. On the other hand, a medication that is activated by metabolism may not work if an enzyme is inactive. Enhanced enzyme activity can also affect the response to medication, e.g. by degrading the active ingredients.

Full List of Genes